Ep204: Troy Wilson on Precision Cancer Drugs and Combos

What It Covers

Troy Wilson, cofounder and CEO of Kura Oncology, traces the path from a mediocre student in Palos Verdes to leading a company that achieved FDA approval in November 2025 for zifdomenib (COMZIFTI), a menin inhibitor for NPM1-mutant AML, while building a second program pairing farnesyltransferase inhibitor darlofarnib with RAS inhibitors for pancreatic cancer.

Key Questions Answered

• •Menin inhibitor mechanism: Zifdomenib works by forcing leukemic blast cells to differentiate into normal cells rather than killing them directly. Those differentiated cells live a few weeks and die naturally. This mechanism produces deep responses and minimal toxicity, with differentiation syndrome as the primary risk — a side effect that largely disappears when zifdomenib is combined with chemotherapy, reducing the tumor burden before differentiation begins.
• •AML market expansion path: Kura's current FDA approval covers relapsed/refractory NPM1-mutant AML, a narrow initial indication. Two global Phase 3 trials enrolling approximately 1,300 patients target frontline AML combining zifdomenib with intensive chemotherapy. Phase 1 data presented at EHA Stockholm shows patients remaining disease-free at two years. Wilson projects peak U.S. revenues up to $3 billion annually if frontline approval covers roughly 50–60% of all AML patients.
• •Resurrecting written-off drug classes: Farnesyltransferase inhibitors failed in the 1990s for three reasons: incomplete biological understanding, absence of next-generation sequencing, and no complementary targeted therapies to combine with. Darlofarnib is approximately 1,000 times more potent than first-generation tipifarnib. The lesson for drug developers: a mechanistically sound target abandoned due to timing and tooling gaps deserves reassessment when the surrounding therapeutic landscape matures sufficiently.
• •Combination strategy with RAS inhibitors: Darlofarnib blocks RAS pathway signaling at the TORC1 node, downstream from where RAS inhibitors like daraxonrasib act. Wilson plans to combine darlofarnib with daraxonrasib in second-line pancreatic ductal adenocarcinoma, targeting resistance pathways that emerge with single-agent RAS inhibition. With daraxonrasib's median overall survival at 13 months, Wilson frames combination therapy as the necessary next step rather than an optional enhancement.
• •Serial entrepreneur compounding: Wilson cofounded four companies — Intellikine (PI3K), Ambryx (ADCs), Avidity Biosciences (antibody-oligonucleotide conjugates, acquired by Novartis for ~$11 billion), and Kura — running several simultaneously in early stages. His framework: each company requires the right organizational build for the specific problem and stage. Early-stage companies need minimal infrastructure; commercial-stage companies require integrated teams spanning discovery through market access to make better upstream decisions.
• •San Diego biotech ecosystem advantage: Wilson identifies two structural reasons San Diego produces disproportionate startup activity: a high density of "two-body problem" scientists — researchers in relationships with other scientists who need a hub with multiple employers — and a cultural tolerance for risk built from repeated startup cycles. Founders who have worked in three or four San Diego startups treat company failure as a transition rather than a career ending event, sustaining a continuous pipeline of experienced risk-takers.